QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
January 25 2022 - 1:30AM
Business Wire
- 70% of all U.S. states now using QIAcuity for ultra-sensitive
wastewater detection of SARS-CoV-2 infections
- Over 35 QIAcuity systems shipped by end-2021 as part of a U.S.
National Institutes of Health (NIH) supply contract for COVID-19
testing solutions
- QIAcuity digital PCR applications for wastewater-based
epidemiology proving to be a vital early-warning surveillance tool
for authorities fighting the pandemic
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced it has completed a U.S. government contract to equip
public health laboratories across the country with the QIAcuity
digital PCR system to monitor the spread of the COVID-19 pandemic
by testing wastewater for the presence of SARS-CoV-2 pathogens.
QIAGEN has shipped more than 35 QIAcuity systems to state and
local health laboratories as part of a multi-million-dollar
contract with the U.S. National Institutes of Health (NIH) to
supply COVID-19 instruments and consumables through the end of
2021.
More than 70% of all U.S. states now have at least one
laboratory – either public health or privately-owned – with a
QIAcuity system for wastewater surveillance. The ultra-sensitive
digital PCR platform has set new standards for delivering rapid
results in two hours rather than the six required by competitive
systems based on a proprietary nanoplate-based system.
“This contract to QIAGEN has allowed public health laboratories
to have rapid access to extraction equipment and supplies that are
enabling them to do both surveillance and wastewater testing to
support pandemic response,” said Scott J. Becker, M.S., Chief
Executive Officer, Association of Public Health Laboratories, in
Silver Springs, Maryland. “This accelerated ability has enabled
public health laboratories to serve communities across the country.
QIAGEN was incredibly responsive to the many needs of APHL member
labs and worked tirelessly to support and address public health
concerns.”
“QIAcuity is an ideal solution to test for SARS-CoV-2 pathogens
in sewage samples, and QIAGEN is ready to support public health
labs in the U.S. and around the world to generate important
insights to complement epidemiological data,” said Thomas Schweins,
Ph.D., Senior Vice President, Life Science Business Area at QIAGEN.
“We are ready to help public health officials set up and operate
processes for this crucial tool to fight the pandemic. Genetic
surveillance is proving its value these days – and will prove to be
a vital tool in the future. As COVID-19 is becoming endemic,
testing needs will increasingly shift from detecting viruses to
monitoring the spread of infectious diseases.”
Surveillance testing allows public authorities to collect data
from broad sweeps of the population, including people who are not
reflected in public-health statistics because they lack access to
healthcare. It can potentially reveal dynamic changes in infections
– and mutations – earlier than traditional diagnostic testing,
providing public-health officials with near-real-time data about
the presence and intensity of the disease.
More information about QIAGEN solutions for wastewater testing
can be found here.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2020, QIAGEN employed approximately 6,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220124005783/en/
QIAGEN: Investor Relations John Gilardi +49 2103
29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024